论文部分内容阅读
目前我国化学原料药和药品制剂生产企业有4700多家,在总体上呈现出多、小、散、低的格局,生产集中度低,自主创新能力不足的问题依然存在。修订我国药品GMP、提高药品GMP实施水平,一方面有利于促进企业优胜劣汰、兼并重组、做大作强,进一步调整企业布局,净化医药市场,防止恶性竞争,同时也是保障人民用药安全有效的需要;另一方面也
At present, there are more than 4,700 chemical raw material and pharmaceutical product manufacturing enterprises in our country, presenting a pattern of multiple, small, scattered and low overall. The problem of low production concentration and insufficient capacity of independent innovation still exists. Amendment of China’s pharmaceutical GMP, improve the level of implementation of pharmaceutical GMP, on the one hand is conducive to promoting the survival of the fittest, mergers and acquisitions, bigger and stronger, to further adjust the layout of the business, to purify the pharmaceutical market, to prevent vicious competition, but also to ensure the safety and effectiveness of people’s needs; On the one hand too